pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics B.V.
Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-S
825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 825 Industrial Rd, Suite 400, San Carlos, California 94070, US
- Founded
- 2007
- Employees
- 916
- Programs
- 36
- Drugs
- 26
- Patents
- 94
Tumor infiltrating lymphocytes (TIL) LN-145
Phase 2 · small molecule · Metastatic Triple Negative Breast Cancer
Tumor infiltrating lymphocytes (TIL) LN-145 for Metastatic Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).
Internal code 2000025837
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Iovance Biotherapeutics B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic Triple Negative Breast Cancer
- Status
- completed
- Trials
- 1